Friday 6 November 2026
Export PLSE’s income statement to Excel — free account
Pulse Biosciences, Inc
PLSE Healthcare Medical Instruments & Supplies
Pulse Biosciences, Inc’s revenue for fiscal 2025 (year ended December 2025) was $350,000.00, down 50.0% from fiscal 2022.
- Revenue
- +359.3%
- EPS
- −10.3%
- Free cash flow
- −1,180.5%
Quarter to September 2026, against a year earlier
52.32
0.75
−1.41%
Follow PLSE
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (60.67%) | (78.49%) | (80.72%) | (74.45%) |
+8 more TTM periods Free account |
|
| (54.01%) | (67.90%) | (69.36%) | (64.12%) | ||
ROIC |
(37.01%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(46.59%) | (83.58%) | (119.59%) | (95.08%) | |
Average Days of Receivables |
72.56 | 37.58 | 77.23 | 165.03 | |
Free Cash Flow per Share |
(3.00) | (0.89) | (0.82) | (0.81) | |
Free Cash Flow |
(216.07) | (61.39) | (55.50) | (54.44) | |
Capital Expenditures |
(152.74) | (0.29) | (0.30) | (0.31) | |
| Other line items | |||||
Cash ROIC |
(98.08%) | (30.52%) | (41.23%) | (33.73%) | |
Accounts Receivable Turnover |
9.58 | 18.66 | 8.99 | 4.11 | |
Accounts Payable Turnover |
0.36 | 0.42 | 0.46 | 0.50 | |
Inventory Turnover |
7.57 | 8.24 | 9.96 | 2.50 | |
Average Days of Payables |
1,006.92 | 874.52 | 857.67 | 915.63 | |
Days of Inventory on Hand |
77.40 | 72.88 | 63.99 | 44.84 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
3,838.09% | 4,378.57% | 6,333.96% | 7,379.70% | |
Selling, General and Administrative Expense of Revenue |
2,009.77% | 2,629.45% | 4,162.94% | 5,285.31% | |
Share Based Compensation of Revenue |
1,149.06% | 1,474.43% | 2,383.83% | 3,540.76% | |
Operating CF/Net income |
0.76 | 0.76 | 0.74 | 0.74 | |
Depreciation/Fixed assets |
0.00 | 0.96 | 1.03 | 1.02 | |
Capex/Depreciation |
0.00 | (0.28) | (0.29) | (0.29) | |
Revenue per Share |
0.02 | 0.02 | 0.01 | 0.01 | |
Operating CF per Share |
(0.88) | (0.88) | (0.81) | (0.80) | |
Capex per Share |
(2.12) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
102.23 | 0.24 | 0.41 | 0.52 |
Columns are period end dates · fundamentals updated 5 Nov 2026